Acquirements of treasury shares up to approximately 3.0 billion yen, acquisition period from 2026\/8\/7 to 2026\/9\/14, shares acquired: 1,038,600 ordinary shares, total amount about 2,999,998,289 yen. Acquisition completed via market purchases. At the time of the March 26, 2026 Board resolution, the cap was 1,500,000 shares and 30 billion yen, with progress showing 69.24% in shares and completed total amount.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4527","jir_company_name":"Lotte Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-09-15","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/4527-20260915-01.pdf","jir_short_summary":"Acquirements of treasury shares up to approximately 3.0 billion yen, acquisition period from 2026\/8\/7 to 2026\/9\/14, shares acquired: 1,038,600 ordinary shares, total amount about 2,999,998,289 yen. Acquisition completed via market purchases. At the time of the March 26, 2026 Board resolution, the cap was 1,500,000 shares and 30 billion yen, with progress showing 69.24% in shares and completed total amount.","jir_summary":"### Acquisition Overview\nLotte Pharmaceutical conducted and completed a treasury share acquisition based on Corporate Act Article 459, Paragraph 1. The target is ordinary shares, with a total acquisition of 1,038,600 shares and total amount of about 29.9998 billion yen. Acquisition period was from August 7, 2026 to September 14, 2026, and the method was market purchases. At the Board resolution, the cap was 1,500,000 shares and 30 billion yen, with progress showing 69.24% of shares acquired and total amount completed.\n\n### Background and Impact\nThis treasury share acquisition is positioned as a shareholder return measure, likely aimed at mitigating dilution and stabilizing shareholder value. With the end of the acquisition period, there may be implications for near-term share float. Attention is needed regarding future capital policy directions and shareholder returns.","jir_financial_highlights":"Total number of treasury shares acquired: 1,038,600 shares (Progress 69.24%)\nTotal amount of acquisition: 2,999,998,289 yen (Progress 100.0%)\nAcquisition period: 2026 August 7 \u2013 2026 September 14 (Unknown)\nTarget shares: Our ordinary shares (Unknown)","jir_category":"","jir_hashtags":"#LottePharmaceuticalTreasuryShareAcquisition","jir_key_figures":"Total number of treasury shares acquired: 1,038,600 shares\nTotal amount of acquisition: 2,999,998,289 yen\nAcquisition period: 2026 August 7 \u2013 2026 September 14","jir_meta_title":"Lotte Pharmaceutical Treasury Share Acquisition Status and Completion | September 2026","jir_meta_description":"Lotte Pharmaceutical acquired treasury shares via market purchases from August 7 to September 14, 2026, totaling 1,038,600 shares and 299,999,8289 yen. Completion achieved. Cap was 1,500,000 shares and 30 billion yen. Attention on future capital policy.","jir_og_title":"Lotte Pharmaceutical Treasury Share Acquisition Update | September 2026","jir_og_description":"Lotte Pharmaceutical has completed treasury share acquisition. Review the number of shares and total amount, and period. Focus on future capital policy as well.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7770,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"share_buyback","footnotes":""},"sector":[],"importance":[],"class_list":["post-114177","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n